Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Bayer
February 21, 2023

Novo sows the seeds for a new heart failure approach

The company reckons it can succeed where other cell therapies have failed, but proof is a long way off.

Thumbnail
January 27, 2023

Anthos doubles down on its novel blood thinner

The group continues its niche-targeting strategy with abelacimab’s latest pivotal trial.

Article image
Vantage logo
January 26, 2023

Xylocor sees enough to press on with angina gene therapy

A pivotal trial is in the works, but can the group succeed where other VEGF gene therapies have failed?

Article image
Vantage logo
January 23, 2023

The world's twelfth VEGF drug will be sold by Takeda

The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.

Article image
Vantage logo
January 09, 2023

JP Morgan 2023 – licensing deal flurry offers limited cash up front

Article image
Vantage logo
November 16, 2022

Lantheus has three shots on goal to challenge Novartis

Two days after tying up with Point the company outlines plans to dominate PSMA-based prostate cancer screening and treatment.

Article image
Vantage logo
November 15, 2022

Lantheus gets to the Point in therapeutics

Lantheus goes further into radioligand therapeutics, but the market thinks its latest push shortchanges Point Biopharma.

Article image
Vantage logo
November 07, 2022

Ionis gets a double whammy

Article image
Vantage logo
September 29, 2022

Go or no go? GSK takes its turn with a novel anaemia class

Amicus and Astrazeneca have notable approaching Pdufa decisions, while a panel for GSK’s daprodustat could change the course of a controversial drug class.

Article image
Vantage logo
September 27, 2022

Ocular Therapeutix joins the long-acting race

But the group has a long way to go to set up a showdown with Eylea.

Article image
Vantage logo
September 09, 2022

Regeneron could reap big rewards from high-dose Eylea

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up